CAH

Business profile & competitive position

Cardinal Health, Inc. sits in the Healthcare sector, specifically Medical - Distribution. The company supplies pharmaceuticals and medical products and provides services aimed at improving healthcare system and supply-chain efficiency. It connects patients, providers, payers, pharmacists, and manufacturers through two main reporting segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD), with smaller operations reported under Other.

The segment economics show up in the margin profile. For fiscal 2026 Cardinal generated $254.2 billion in total revenue but reported a net margin of only 0.7%. That spread is typical of a high-turnover distributor that earns its profit through volume, sourcing relationships, and fee-based services rather than large markups on individual products.

The -59.7% ROE is the more striking figure. Because ROE equals net income divided by shareholders’ equity, a negative ROE alongside a positive 0.7% net margin means Cardinal’s book equity is negative. The business is profitable at the net-income line, but shareholders’ equity is below zero, so the traditional return-on-equity metric reads as deeply negative and is not a clean gauge of competitive moat by itself.

Financial posture

Cardinal carries a market capitalization of $55.1 billion and trades at a trailing P/E of 32.4. That multiple looks high relative to the 0.7% net margin and the -59.7% ROE, but it aligns more closely with the company’s non-GAAP operating earnings growth: fiscal 2026 non-GAAP operating earnings rose 30% to $3.6 billion, while GAAP operating earnings rose 15% to $2.6 billion. The valuation therefore appears to reflect operating leverage and specialty-services expansion rather than bottom-line margin alone.

The stock’s recent snapshot shows a price of $235.22, an RSI of 55.7, and a 50-day EMA of $230.72. The beta is 0.50, suggesting the shares have historically moved about half as much as the broader equity market, consistent with a healthcare-services/defensive profile.

Strategic priorities & outlook

Cardinal’s most recent 10-K outlines four near-term operational focuses. First, it plans to expand and integrate the Specialty Alliance multi-specialty MSO platform and other recently acquired physician-practice support platforms to capture expected strategic value. The company completed the acquisition of Solaris Health, a urology MSO, on November 3, 2025, for roughly $1.9 billion, and afterward owned approximately 76% of The Specialty Alliance.

Second, in the GMPD segment Cardinal is trying to reduce tariff impacts through cost optimization and by increasing prices on impacted products. Third, management is focused on managing the Pharma generics program, including product launches, customer volumes, pricing, Red Oak Sourcing, and contract manufacturing/sourcing costs. Fourth, the company is targeting approximately $700 million in fiscal 2027 capital expenditures for manufacturing, distribution infrastructure, and technology investments.

Those priorities fit the fiscal 2026 numbers. Total revenue increased 14% to $254.2 billion, Pharma segment revenue grew 15% to $234.8 billion on branded and specialty pharmaceutical growth, and both non-GAAP and GAAP operating earnings posted double-digit gains.

Macro & geopolitical exposure

As a large healthcare distributor, Cardinal sits at the intersection of regulated pharmaceutical supply chains, global medical-product sourcing, and reimbursement policy. Trade policy is a live issue: the 10-K explicitly flags tariff impacts in the GMPD segment and counters them with cost optimization and price increases. Currency fluctuation and supply-chain interruptions can also affect product costs and availability, especially for medical products and components sourced internationally.

On the regulatory side, pharmaceutical distributors face drug-pricing, reimbursement, and compliance risks, including controlled-substance distribution rules and generic-drug pricing pressure. Interest rates influence working-capital financing and inventory carrying costs, while changes in federal or state healthcare policy can shift demand and margins across both the Pharma and GMPD segments. Cardinal’s low beta of 0.50 suggests the stock has historically been less volatile than the broader market, but its operational sensitivity to healthcare regulation and trade policy is inherent to the industry.

Recent developments

Recent headlines have been modestly positive on performance but mixed on institutional flow. On October 6, 2026, zacks.com published “Reasons to Retain Cardinal Health Stock in Your Portfolio for Now,” and on October 5, 2026, zacks.com noted “Cardinal Health (CAH) Outperforms Broader Market: What You Need to Know.” Both pieces captured relative-strength and retention arguments heading into the fall.

Institutional activity reported on October 5, 2026, by defenseworld.net was split. Park National Corp OH decreased its Cardinal Health position, while MassMutual Private Wealth & Trust FSB bought 106,709 shares. So the same day brought a divestiture from one professional investor and a meaningful purchase from another.

Earnings behavior & post-earnings drift

Cardinal has beaten earnings estimates in all eight of the last reported quarters—a 100% beat rate—with an average earnings surprise of 12.5%. That consistency would normally suggest a reliable “beat and rally” setup, but the post-earnings price behavior tells a different story. Across those same quarters, the average 5-day price move in the sessions after the report was -1.8%, classified as a “down” drift.

The last four quarters make the disconnect even clearer. On August 11, 2026, CAH reported EPS of $2.91 versus the $2.42 estimate, a 20.2% surprise, yet the stock fell 2.54% the next day and 2.2% over the following five days. On April 30, 2026, EPS of $3.17 beat the $2.79 estimate by 13.6%, with a next-day gain of 1.22% but a five-day decline of 3.94%. On February 5, 2026, EPS of $2.63 beat the $2.34 estimate by 12.4%, yet the stock dipped 0.38% the next day and dropped 5.33% over the next five sessions. The October 30, 2025 report was the exception: EPS of $2.55 beat the $2.18 estimate by 17.0%, rose 0.49% the next day, and gained 4.29% over the next five days.

In short, three of the last four beats were followed by negative five-day drift even though the reported results were above the market’s real expectation. That pattern points to expectations being bid up ahead of the release, leaving little directional follow-through once the numbers land. Cardinal Health is scheduled to report next on November 5, 2026, before the market opens, with a consensus EPS estimate of $2.95.

For a deeper dive into how institutional analysts are positioned ahead of the November 5, 2026 earnings report, review the full institutional verdict and aggregate ratings for CAH.